Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
NCT04781335: "A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation"

Recruiting
4
50
US
Dexycu, Standard of Care post operative eye drops (steroid, antibiotic, NSAID)
The Eye Institute of West Florida, EyePoint Pharmaceuticals, Inc.
Cataract
06/21
08/21
NCT06497699: A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery

Completed
4
263
RoW
Dexycu
Ocumension Therapeutics (Shanghai) Co., Ltd
Inflammation, Cataract
07/23
12/23
NCT05191706: Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Recruiting
4
60
US
Dexamethasone, Prednisolone Acetate Ophthalmic
EyePoint Pharmaceuticals, Inc.
Cataract
01/25
02/25

Download Options